A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
Istituto Oncologico Veneto IRCCS
AstraZeneca
Essen Biotech
Essen Biotech
University of Nebraska
Conjupro Biotherapeutics, Inc.
Memorial Sloan Kettering Cancer Center
Natera, Inc.
Second Life Therapeutics
Elephas
Elephas
University Health Network, Toronto
Massive Bio, Inc.
UNC Lineberger Comprehensive Cancer Center
MacroGenics
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine
Delfi Diagnostics Inc.
Milton S. Hershey Medical Center
Columbia University
Tempus AI
Tvardi Therapeutics, Incorporated
Taproot Health
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NantBioScience, Inc.
Xencor, Inc.
Pfizer
Cancer Support Community, Research and Training Institute, Philadelphia
Pfizer
Celldex Therapeutics
Massachusetts General Hospital
Klus Pharma Inc.
National Institutes of Health Clinical Center (CC)
Xencor, Inc.
Bristol-Myers Squibb
Quadriga Biosciences, Inc.
Xencor, Inc.
Pfizer
Hospices Civils de Lyon
National Institutes of Health Clinical Center (CC)
SpeciCare
MultiVir, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
CureOne
Stanford University
Santa Maria Biotherapeutics
OrienGene Biotechnology Ltd.
University of Pittsburgh